港股医药股盘中爆发！港股创新药ETF（159567）直线拉升逾2%，8月以来累计吸金超17亿元

Group 1 - Hong Kong pharmaceutical stocks experienced a rapid increase, with Rongchang Biopharmaceutical rising over 8%, and Green Leaf Pharmaceutical, CSPC Pharmaceutical, and Junshi Biosciences each rising over 5% [1] - The Hong Kong Innovative Drug ETF (159567) surged over 2%, reflecting strong market interest [1] - The Innovative Drug ETF has seen continuous net inflows for four consecutive trading days, accumulating over 1.7 billion yuan since August [1] Group 2 - Major pharmaceutical companies are significantly increasing their procurement of innovative drug patents in China, with procurement amounts from January to May nearing the total for the entire year of 2024, indicating the competitiveness of Chinese innovative drugs in the international market [1] - Upcoming major conferences, including the World Lung Cancer Conference (WCLC) in September and the European Society for Medical Oncology (ESMO) in October, will showcase research results from domestic innovative drugs, enhancing their global competitiveness [1] - The Hong Kong Innovative Drug ETF tracks the CSI Hong Kong Stock Connect Innovative Drug Index, aiming to reflect the performance characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1]